AP
IRON icon

Antipodes Partners’s Disc Medicine IRON Stock Holding History

Antipodes Partners’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-476
Closed -$30.4K – 140
2026
Q1 		$30.4K Buy
476
+57
+14% +$3.96K ﹤0.01% 115
2025
Q4 		$33.3K Buy
+419
New +$35.4K ﹤0.01% 116

Other funds holding IRON

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
IGAM
iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Antipodes Partners's IRON Position: Q2 2026 in Review

Antipodes Partners sold out of Disc Medicine (IRON) in Q2 2026, closing a stake of 476 shares — an estimated $30.4K sold.

Antipodes Partners first reported a position in IRON in Q4 2025 and held it in 2 quarters. The position peaked at $33.3K in Q4 2025. 63 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • Antipodes Partners reported no remaining Disc Medicine position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 476 Disc Medicine shares in Q2 2026, an estimated $30.4K.
  • Antipodes Partners first reported a position in Disc Medicine in Q4 2025 and held it in 2 quarters.
  • Antipodes Partners's Disc Medicine position peaked at $33.3K in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.